en.Wedoany.com Reported, March 31, 2026 - Innovent Biologics and its partner Ollin Biosciences today announced the final 20-week data from the JADE clinical study. This study is a randomized, head-to-head Phase 1b trial designed to compare OLN324 with faricimab (Vabysmo®) in treating patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD).

The final results showed that OLN324 outperformed faricimab in terms of durability and anatomical control. For patients with diabetic macular edema (DME), the OLN324 treatment group demonstrated more significant retinal drying and less need for retreatment at week 20. In wAMD, OLN324 also showed a sustained advantage in visual acuity gain, with faster and more durable control of pigment epithelial detachments (PEDs).

The JADE trial enrolled a total of 164 U.S. patients. All participants initially received three months of monthly dosing, followed by 12 weeks of follow-up. The data showed that among DME patients treated with OLN324 4 mg, 93% did not require retreatment during the follow-up period, compared to 89% in the faricimab group. Among wAMD patients, 82% in the OLN324 group did not require retreatment, compared to 81% in the faricimab group.

Regarding safety, no cases of intraocular inflammation were reported in the OLN324 group throughout the study, while one case occurred in the faricimab group. No cases of retinal vasculitis or occlusive retinal vasculitis were observed.

Jason Ehrlich, MD, PhD, Co-founder and CEO of Ollin Biosciences, stated, "These data reinforce the differentiated profile of OLN324, highlighting its robust efficacy and durability in DME and wAMD. Combined with a favorable safety profile, OLN324 has the potential to become a first-line treatment option for these vision-threatening diseases. We plan to initiate global Phase 3 studies later this year and are collaborating with Innovent to plan the inclusion of patients from China and South Korea."

Qian Lei, MD, PhD, Chief Scientific Officer of General Biomedicine at Innovent Biologics, added, "We are pleased to see that the latest data for OLN324 further highlight its clinical potential. We will continue to work closely with Ollin to accelerate the global Phase 3 clinical development for this retinal disease program."

Full details of the JADE study are expected to be presented at future medical and scientific meetings. OLN324 is a next-generation VEGF/Ang2 bispecific antibody discovered and co-developed by Innovent Biologics, aiming to provide a superior treatment option for retinal vascular diseases.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com